Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Laboratories Validate New Clinical Test for Acute Kidney Injury

By LabMedica International staff writers
Posted on 12 Mar 2014
Using clinical adjudication, a multicenter prospective study validates a simple new urine test for two biomarkers identified for acute kidney injury.

The study validated the performance of the NephroCheck Test, from Astute Medical (San Diego, CA, USA), in assessing critically ill patient risk of developing acute kidney injury (AKI). More...
The abrupt loss of kidney function in AKI usually occurs within 48 hours, making currently used AKI markers insufficient, as they are not detected until several hours after AKI has already begun.

The NephroCheck Test utilizes fluorescence immunoassay technology to detect and measure two urine biomarkers of AKI: tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) released by kidney cells during acute stress. When assessed together they enable clinicians to begin treating AKI much earlier than current standards. In the study, 420 critically ill patients in 23 medical centers were enrolled. The primary analysis was the ability of the biomarkers to predict moderate to severe AKI within 12 hours of test measurement. AKI was adjudicated by a committee of three independent expert nephrologists who were blinded to the results.

“This first-of-its-kind study utilized clinical adjudication, the most rigorous standard, to prospectively validate two biomarkers for risk assessment of AKI,” said first author Dr. Azra Bihorac of the University of Florida (USA). “Our study found that the product of the two biomarkers can identify a high risk for near-term AKI in a wide range of critically ill patients. These are the very patients needing improved delivery of recommended interventions, such as those included in the KDIGO [Kidney Disease Improving Global Outcomes] guideline.” Unlike heart attack, AKI lacks clinical symptom warning signs in the early stages when intervention is most beneficial. In addition, AKI has been especially associated with higher cost-of-care and length-of-stay in intensive care units.

The validation study was reported by Bihorac A. et al. in the American Journal of Respiratory and Critical Care Medicine, February 21, 2014, online, ahead of print. The Jortani Clinical Trials Laboratories (JCTL) at the University of Louisville (Louisville, KY, USA) were among the independent labs that tested the trial results. As a Clinical Laboratories Improvement Amendments (CLIA)-certified lab, the JCTL has undergone a rigorous review of its facilities and processes to ensure quality in laboratory testing and analyses. Other main laboratories involved included those at the University of California (San Diego, CA, USA), ARUP Laboratories (Salt Lake City, UT, USA), University of Pittsburgh, (Pittsburgh, PA, USA), and University of Florida (Gainesville, FA, USA).

Related Links:

Astute Medical



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.